Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBIT (2020 - 2025)

Historic EBIT for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$14.5 million.

  • Tarsus Pharmaceuticals' EBIT rose 4225.82% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.4 million, marking a year-over-year increase of 3782.7%. This contributed to the annual value of -$120.6 million for FY2024, which is 1577.91% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' EBIT is -$14.5 million, which was up 4225.82% from -$22.2 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' EBIT peaked at $10.7 million during Q1 2021, and registered a low of -$44.4 million during Q4 2023.
  • Moreover, its 5-year median value for EBIT was -$22.9 million (2022), whereas its average is -$21.1 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 60585.46% in 2021, then tumbled by 52827.34% in 2023.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' EBIT stood at -$14.4 million in 2021, then decreased by 4.24% to -$15.1 million in 2022, then plummeted by 195.13% to -$44.4 million in 2023, then surged by 45.06% to -$24.4 million in 2024, then surged by 40.51% to -$14.5 million in 2025.
  • Its last three reported values are -$14.5 million in Q3 2025, -$22.2 million for Q2 2025, and -$26.3 million during Q1 2025.